Treatment of hyperlipidemia from Japanese evidence

Journal of Atherosclerosis and Thrombosis

Volumn 13, Issue 6, 2006, Pages 267-280

  Koba, Shinji ^a   Sasaki, Jun ^a,b  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Cardiovascular disease; Coronary heart disease; Epidemiological study; Hyperlipidemia; Lipid lowering therapy; Randomized controlled trial

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ASIAN; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; JAPAN; REVIEW;

ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, HDL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; JAPAN;

EID: 39049188743     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13.267     Document Type: Review

References (69)

1. Saito Y: The Japan Atherosclerosis Society Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Disease 2002 (Editorial). J Atheroscler Thromb, 2004; 11:101-103
2. Grundy SM, Cleeman JI, Merz NB, Brewer Jr B, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC, Stone NJ, for the coordinating committee of the National Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 2004; 110:227-239
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, MangerCats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, and Wood D: European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J, 2003; 24:1601-1610
4. Ginsberg HN: Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease. Curr Cardiol Reports, 1999; 1:233-237
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4). Lancet, 1994; 344:1383-1389
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med, 1995; 333:1301-1307
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med, 1996; 335:1001-1009
8. Downs JR, Clearfield M, Weis S, Whitney F, Shapiro D, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto Jr AM, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TeCAPS. JAMA, 1998; 279:1615-1662
9. The Long-Term Intervention with Pravastatin Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339:1349-1357
10. Shepherd J, Blauw GJ, Murphy MB, Bollen ELE, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry I, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, on behalf of the PROSPER study group. Pravastatin in elderly individuals at rsik of vascular disease (PROSPER): a randomized controlled trial. Lancet, 2002; 360:1623-1630
11. Sever PS, Dahlöf B, Roulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes CT, Mehlsen J, Nieminen M, O'Brien E, Östergren J, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concnentrtaions, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancer, 2003; 361:1149-1158
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet, 2002; 360:7-22
13. Colhoun HM, Betteridge DJ, Durrington PN, Hitman G, Neil HAW, Livingstone SJ, Thomason MJ, Mackness KI, Charlton-Menys V, Fuller JH, on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet, 2004; 364:685-696
14. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Dermitriadis DS, and Kontopoulos AG: Treatment with atorvastatin to the National Cholesterol Education program goal versus 'usual' care in secondary coronary heart disease prevention - the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Curr Med Res Opin, 2002; 18:220-228
15. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, and Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke, 2003; 34:2349-2354
16. Sytkowski PA, D'Agostino RB, Belanger A, and Kannel WB: Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950-1989. Am J Epidemiol, 1996; 143:338-350
17. Yoshida M, Kita Y, Nakamura Y, Nozaki A, Okayama A, Sugihara H, Kasamatsu T, Hirose K, Kinoshita M, and Ueshima H: Incidence of acute myocardial infarction in Takashima, Shiga, Japan. Circ J, 2005; 69:404-408
18. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet, 2006; 368:1155-1163
19. Yokoyama M: Effects of eicosapentaenoic acid (EPA) on major cardiovascular events in hyperchoelsterolemic patients: the Japan EPA Lipid Intervention Study (JELIS). Circulation, 2005; 112:3362 [abstract]
20. Kodama K, Sasald H, and Shimizu Y: Trend of coronary heart disease and its relationship to risk factors in a Japanese Population: A 26-year follow-up, Hiroshima/Nagasaki Study. Jpn Circ J, 1990; 54:414-421
21. Benfante R: Studies of cardiovascular disease and cause-specific mortality trends in Japanese-American men living in Hawaii and risk factor comparison with other Japanese populations in the Pacific region: A review. Hum Biol, 1992; 64:791-805
22. Kromhout D: On the waves of the Seven Countries Study. A public health perspective on cholesterol. Eur Heart J, 1999; 20:796-802
23. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Kita T, on behalf of the Research Group on Serum Lipid Level Survey 2000 in Japan. J Atheroscler Thromb, 2005; 12:98-106
24. Okamura T, Kadawaki T, Hayakawa T, Kita Y, Okayama A, Ueshima H, for the NIPPON DATA 80 Research Group. What cause of mortality can we predict by cholesterol screening in the Japanese general population? J Intern Med, 2003; 253:169-180
25. Okamura T, Tanaka H, Miyamatsu N, Hayakawa T, Kadowaki T, Kita Y, Nakamura Y, Okayama A, Ueshima H, for the NIPPON DATA 80 research group. The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3 year study of a Japanese cohort. Atherosclerosis 2006, Mar 8 [Epub ahead of print]
26. Wakugami K, Iseki K, Kimura Y, Okumura K, Ikemiya Y, Muratani H, and Fukiyama K: Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan. Jpn Circ J, 1998; 62:7-14
27. Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, and Fujishima M: Incidence and risk factors for subtypes of cerebral infarction in a general population. The Hisyama Study. Stroke, 2000; 31:2616-2622
28. NIPPON DATA 80 Research Group. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese Representative Population-NIPPON DATA 80-. Circ J, 2006; 70:1249-1255
29. Tanaka H, Date C, Chen H, Nakayama T, Yokoyama T, Yoshiike N, Iwaoka H, Iwaya M, Zaman MM, Yamaguchi M, Matsumura Y, Sugiyama M, Kushiro W, Ichimura T, Noji A, Chowdhury AH, Kim IS, Kwan TB, and Cho BM: A brief review of epidemiological studies on ischemic heart disease in Japan. J Epidemiol, 1996; 6:S49-S59
30. Konishi M, Iso H, Iida M, Naito Y, Sato S, Komachi Y, Shimamoto T, Doi M, and Ito M: Trends for coronary heart disease and its risk factors in Japan: Epidemiologic and pathologic studies. Jpn Circ J, 1990; 54:428-437
31. Okayama A, Ueshima H, Marmot M, Elliott P, Choudhury SR, and Kita Y: Generational and regional differences in trends of mortality from ischemic heart disease in Japan from 1969 to 1992. Am J Epidemiol, 2001; 153:1191-1198
32. Khoo KL, Tan H, Liew YM, Deslypere JP, and Janus E: Lipids and coronary heart disease in Asia. Atherosclerosis, 2003; 169:1-10
33. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, and Komachi Y: Serun triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol, 2001; 153:490-499
34. Asia Pacific Cohort Collaboration. Serum triglyceride as a risk factor for cardiovascular diseases in the Asia-Pacific Region. Circulation, 2004; 110:2678-2686
35. Asia Pacific Cohort Collaboration. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. Ann Epidemiol, 2005; 15:405-413
36. Grundy SM, Cleeman JI, Daniels SR, Donate KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, and Costa F: Diagnosis and Management of the Metabolic syndrome An American Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005; 112:2735-2752
37. Zimmet P, Magliano D, Matsuzawa Y, Albert G, and Shaw J: The Metabolic syndrome: A global public healthy problem and a new definition. J Atheroscler Thromb, 2005; 12:295-300
38. Kukita H, Hamada M, Hiwada K, and Kokubu T: Clinical significance of measurement of serum apolipoprotein A-I, A-II and B in hypertriglyceridemic male patients with and without coronary artery disease. Atherosclerosis, 1985; 55:143-149
39. Washio M, Sasazuki S, Kodama H, Yoshimasu K, Liu YK, Tanaka K, Tokunaga S, Kono S, Arai H, Koyanagai S, Hiyamuta K, Doi Y, Kawano T, Nakagaki O, Takada K, Nii T, Shirai K, Ideishi M, Arakawa K, Mohri M, and Takeshita A: Role of hypertension, dyslipidemia and diabetes mellitus in the development of coronary atherosclerosis in Japan. Jpn Circ J, 2001; 65:731-737
40. Koba S, Hirano T, Kondo T, Shibata M, Suzuki H, Murakami M, Geshi E, and Katagiri T: Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart diseases. Am Heart J, 2002; 144:1026-1035
41. Koba S, Hirano T, Ito Y, Tsunoda F, Yokota Y, Ban Y, Iso Y, Suzuki H, and Katagiri T: Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis, 2006; 189:206-214
42. Kitamua A, Iso H, Naito Y, Iida M, Konishi M, Folsom AR, Sato S, Kiyama M, Nakamura M, Sankai T, Shimamoto T, and Komachi Y: High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation, 1994; 89:2533-2539
43. St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, and Lamarche B: Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol, 2005; 25:553-559
44. Kathiresan S, Gona P, Larson MG, Vita JA, Mitchell GF, Tofler GH, Levy D, Newton-Cheh C, Wang TJ, Benjamin EJ, and Vasan RS: Increased small low-density lipoprotein particle number. A prominent feature of the Metabolic syndrome in the Framingham Heart Study Circulation, 2006; 113:20-29
45. Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD, and Sharp DS: Low-density lipoprotein particle size, triglyceride, and high-density liporpotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol, 2000; 86:412-416
46. Matsuzawa Y, Itakura H, Kita T, Mabuchi H, Mastuzaki M, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, the J-LIT Study Group. Design and baseline characteristics of a cohort study in Japanese patients with hypercholesterolemia: The Japan Lipid Intervention Trial (J-LIT). Curr Ther Res, 2000; 61:219-243
47. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, and the J-LIT Study Group. Large-scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia - primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT)-. Circ J, 2002; 66:1087-1095
48. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, and the J-LIT Study Group. Large-scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease - secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J, 2002; 66:1096-1100
49. Nakaya N, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, and the J-LIT Study Group. Large-scale cohort study on the relationship between lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia - sub-analysis of the Japan Lipid Intervention Trial (J-LIT). Circ J, 2005; 69:1016-1021
50. The Kyushu Lipid Intervention Study Group. Pravasatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: The Kyushu Lipid Intervention Study. J Atheroscler Thromb, 2000; 7:110-121
51. Iwashita M, Matsushita Y, Sasaki J, Arakawa K, Kono S, for the Kyushu Lipid Intervention Study (KLIS) Group. Relation of serum total cholesterol and other risk factors to risk of coronary events in middle-aged and elderly Japanese men with hypercholesterolemia - The Kyushu Lipid Intervention Study-. Circ J, 2004; 68:405-409
52. Ito H, Ouchi Y, Ohashi Y, Saito Y, Ishikawa T, Nakamura H, and Orimo H: A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: The Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE). J Atheroscler Thromb, 2001; 8:33-44
53. Mizuno K, Nakamura H, MEGA Study Group. Marked risk reduction in coronary heart disease, stroke and total mortality in women ≥ 60 years old with low-dose pravastatin for primary prevention in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. J Am Coll Cardiol, 2006; 47:354A [abstract]
54. Nakamura Y, Ueshima H, Okamura T, Kadowaki T, Hayakawa T, Kita Y, Tamaki S, Okayama A, for the NIPPON DATA 80 Research Group. Association between fish consumption and all-cause and cause-specific mortality in Japam: NIPPON DATA 80, 1980-1999. Am J Med, 2005; 118:239-245
55. Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S, for the JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Healthy Center-Based (JPHC) Study Cohort I. Circulation, 2006; 113:195-202
56. Law MR, Wald NJ, and Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003; 326:1423-1427
57. Cannon CP, Branwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MC, Skene AM, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350:1495-1504
58. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352:1425-1435
59. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. JAMA, 2005; 294:2437-2445
60. Zhou Z, Rahme E, and Pilote L: Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J, 2006; 151:273-281
61. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from from 90056participants in 14 randomised trials of sataints. Lancet, 2005; 366: 1267-1278
62. Studer M, Briel M, Leimenstoll B, Glass TR, and Bucher HC: Effect of different antilipidemic agents and diets on mortality: A systematic review. Arch Intern Med, 2005; 165:725-730
63. Stone NJ: Fish consumption, fish oil, lipids, and coronary heart disease. Circulation, 1996; 94:2337-2340
64. Prescott SM and Stenson WF: Fish oil fix. Nature Med, 2005; 11:596-598
65. Kajinami K, Okabayashi M, Sato R, Polisecki E, and Schaefer EJ: Statin pharmacogenomics: what have we learned, and what remains unanswered? Curr Opin Lipid, 2005; 16:606-613
66. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillian G, Neaton J, Nelson J, Potter J, Rifkind B, Rossouw J, Shekelle R, Yusuf S, for Participants in the Conference on Low Cholesterol: Mortality Associations. Report of the conference on low blood cholesterol: Mortality associations. Circulation, 1992; 86:1046-1060
67. Dale KM, Coleman CJ, Henyan NN, Kluger J, and White CM: Stains and cancer risk: A meta-analysis. JAMA, 2006; 295:74-80
68. Okumura K, Iseki K, Wakugami K, Kimura Y, Muratani H, Ikemiya Y, and Fukiyama K: Low serum cholesterol as a risk factor for hemorrhagic stroke in men: A community-based mass screening in Okinawa, Japan. Jpn Circ J, 1999; 63:53-58
69. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet, 1998; 352:1801-1807